Man Group
VRDN icon

Man Group’s Viridian Therapeutics VRDN Stock Holding History

Man Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,200
Closed -$566K – 2599
2025
Q4 		$566K Buy
+18,200
New +$499K ﹤0.01% 1860
2023
Q4 		– Hold
0
– -$581K – 2275
2023
Q3 		– Sell
-20,400
Closed -$389K – 1470
2023
Q2 		$485K Buy
+20,400
New +$523K ﹤0.01% 1596
2018
Q4 		– Sell
-882
Closed -$74K – 2132
2018
Q3 		$74K Sell
882
-126
-13% -$11.9K ﹤0.01% 2056
2018
Q2 		$97K Sell
1,008
-1,147
-53% -$121K ﹤0.01% 2071
2018
Q1 		$227K Buy
+2,155
New +$234K ﹤0.01% 1899

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return